Back to Atlas
BSemi-durableResearch-only / high verification need
CMP-0245
Approved in some countries/investigational US
Thymosin Alpha-1
Immunology
Immune-response support and antiviral/oncology adjunct positioning
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Peptide
- Primary mechanism
- T-cell/innate immune modulation
- Primary market use
- Immunology
Pharmacology
- Molecular weight (Da)
- 3108.3
- Oral bioavailability
- N/A
- Half-life
- ~2 h
- Route tags
- Route-dependent / verify
- Evidence level
- Human
- Clinical status
- Approved in some countries/investigational US
- Value-for-money score
- 6 / 10
Reported protocol signal
SQ: • 450 mcg daily for 30 days (Peptide Dosing Guide) • 90 mcg daily for 1 month (for a total of 5 mg) (Tailor Made Compounding Catalog) • 1.5 mg every third day for two weeks for viral infection or up to three months for HIV, cancer, Hepatitis B/C, or complicated immune suppression (Dr. Seeds)
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Functional immune adaptation candidate